Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Minjee Kim(Massachusetts Eye and Ear Infirmary), Jann N. Sarkaria(Mayo Clinic in Arizona), James Watters(Sanofi (France)), Karen E. Parrish(University of Minnesota), Rachael A. Vaubel(Mayo Clinic), William F. Elmquist(University of Minnesota), Jeanette E. Eckel‐Passow(Mayo Clinic in Florida), Ian F. Parney(Mayo Clinic), Aaron J. Johnson(Mayo Clinic), Nathalie Y.R. Agar(Texas Endosurgery Institute), Laurent Debüssche(Sanofi (France)), J. Daniel(Mayo Clinic), David Calligaris(Texas Endosurgery Institute), Ryan W. Feathers(Mayo Clinic in Florida), Paul A. Decker(University of California, San Francisco), Fang Jin(Qingdao University), Isabelle Meaux(Sanofi (France)), Ann C. Mladek(Mayo Clinic), Gaspar J. Kitange(Hormel (United States)), Cédric Barrière(Sanofi (France)), Panos Z. Anastasiadis(Mayo Clinic in Florida), Shulan Tian(Mayo Clinic), Shuangling Zhang(Qingdao Agricultural University)
Cited by 40
Related Papers
Estimating Survival in Patients With Lung Cancer and Brain Metastases
|JAMA Oncology|2016|655
Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy
|Science Translational Medicine|2013|510
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
|Neuro-Oncology|2008|387
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
|Science Immunology|2022|366